Joshua Baker is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Pilot and Feasibility Study of Anti-CD14 for the Treatment of Knee Osteoarthritis
Sponsor: VA Office of Research and Development
- Rehabilitation for Arthritis of The Knee: mainTaining Improvement for Veterans
Sponsor: VA Office of Research and Development
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AmgenProgram year20242 paymentsResearch$68,467
- PfizerProgram year20243 paymentsResearch$4,470
- PfizerProgram year20231 paymentResearch$3,200
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.1%Folate Analog Metabolic Inhibitor23.8%Methotrexate100%Part D≥12 patientsTNF inhibitor4.3%Humira100%Part D<11 patientsMusculoskeletal
20.6%Alkaloid7.8%Colchicine100%Part D<11 patientsNonsteroidal Anti-inflammatory Drug7.1%Diclofenac Sodium100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
18.5%Corticosteroid13.2%Prednisone100%Part D≥12 patientsAminosalicylate5.3%Sulfasalazine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2013–2025 per NIH RePORTER. The latest:
- A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee
Philadelphia Va Medical Center
FY2025I01RX003644 - Adipokines as Biomarkers of Cachexia and High-Risk Rheumatoid Arthritis
Philadelphia Va Medical Center
FY2023I01CX001703
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”